RU2006139030A - Ингибиторы gsk-3 - Google Patents
Ингибиторы gsk-3 Download PDFInfo
- Publication number
- RU2006139030A RU2006139030A RU2006139030/04A RU2006139030A RU2006139030A RU 2006139030 A RU2006139030 A RU 2006139030A RU 2006139030/04 A RU2006139030/04 A RU 2006139030/04A RU 2006139030 A RU2006139030 A RU 2006139030A RU 2006139030 A RU2006139030 A RU 2006139030A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- disease
- unsubstituted
- compound
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
Claims (22)
1. Соединение общей формулы (I)
в которой R1 обозначает органическую группу, содержащую по меньшей мере 8 атомов, выбранных из C или О, которая не связана непосредственно с N через -C(O)- и включающую по меньшей мере ароматическое кольцо;
Ra, Rb, R2, R3, R4, R5, R6 независимо выбраны из водорода, замещенного или незамещенного алкила, замещенного или незамещенного циклоалкила, замещенного или незамещенного алкенила, замещенного или незамещенного арила, замещенного или незамещенного гетероциклила, -COR7, -C(O)OR7, -C(O)NR7R8, -C=NR7, -CN, -OR7, -OC(O)R7, -S(O)t-R7, -NR7R8, -NR7C(О)R8, -NO2, -N=CR7R8 или галогена,
причем Ra и Rb вместе могут образовывать группу =О, и причем любая из пар Ra R2, R2 R3, R3 R4, R4 R5, R5 R6, R6 Rb или R7 R8 может образовывать циклический заместитель;
t=0, 1, 2 или 3,
R7 и R8, каждый независимо, выбраны из водорода, замещенного или незамещенного алкила, замещенного или незамещенного циклоалкила, замещенного или незамещенного алкенила, замещенного или незамещенного арила, замещенного или незамещенного гетероциклила, замещенного или незамещенного алкокси, замещенного или незамещенного арилокси, галогена;
или его фармацевтически приемлемая соль, пролекарство или сольват.
2. Соединение по п.1, в котором R1 имеет по меньшей мере 10 ароматических атомов углерода.
3. Соединение по п.1, в котором ароматический радикал непосредственно связан с N тиадиазолидина.
4. Соединение по п.3, в котором R1 обозначает замещенный или незамещенный нафтил.
5. Соединение по п.4, в котором R1 обозначает замещенный или незамещенный альфа-нафтил, предпочтительно, незамещенный альфа-нафтил.
7. Соединение по п. 1, в котором и Ra и Rb обозначают Н.
8. Соединение по п. 1, в котором R2, R3, R4, R5, R6 независимо выбраны из водорода, замещенного или незамещенного алкила, COR7, -C(O)OR7, -OR7, -NR7R8 или галогена, где R7 и R8 имеют значения, определенные в п.1.
9. Соединение по п.8, в котором R2, R3, R4, R5, R6 обозначают Н.
13. Фармацевтическая композиция, которая включает соединение по любому из пп.1-10 или его фармацевтически приемлемую соль, пролекарство или сольват и фармацевтически приемлемую основу, адъювант или носитель.
14. Фармацевтическая композиция по п.13 для перорального введения.
15. Применение соединения по любому из пп.1-10 в получении лекарственного средства.
16. Применение по п.15, в котором лекарственное средство предназначено для лечения опосредуемого GSK-3 заболевания или состояния.
17. Применение по п.16, в котором заболевание или состояние представляет собой диабет, состояния, связанные с диабетом, хронические нейродегенеративные состояния, включая деменции, такие как болезнь Альцгеймера, болезнь Паркинсона, прогрессирующий надъядерный паралич, подострый склерозирующий панэнцефалитный паркинсонизм, постэнцефалитный паркинсонизм, боксерский энцефалит, комплекс острова Гуам, болезнь Пика, кортикобазальную дегенерацию, лобно-височную деменцию, болезнь Гентингтона, СПИД-деменцию, боковой амиотрофический склероз, рассеянный склероз и нейротравматические заболевания, такие как острый инсульт, эпилепсия, нарушения настроения, такие как депрессия, шизофрения и биполярные нарушения, поддержка функционального восстановления после инсульта, мозговое кровотечение, например, вследствие солитарной церебральной амилоидной ангиопатии, выпадение волос, ожирение, атеросклеротическое сердечно-сосудистое заболевание, артериальную гипертензию, поликистозный синдром яичника, синдром X, ишемию, повреждение головного мозга, травматическое повреждение головного мозга, рак, лейкопению, синдром Дауна, заболевание с тельцами Леви, воспаление, хронические воспалительные заболевания, рак и гиперпролиферативные заболевания, такие как гиперплазии, и иммунодефицит.
18. Применение по п.17, в котором заболевание представляет собой болезнь Альцгеймера.
19. Применение по п.17, в котором заболевание представляет собой диабет типа II.
20. Применение по п.17, в котором заболевание представляет собой депрессию.
21. Применение по п.17, в котором заболевание представляет собой повреждение головного мозга.
22. Применение соединений формулы (I), определенной в любом из пп.1-10, в качестве реагентов для биологических проб, предпочтительно в качестве реагентов для ингибирования GSK-3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04075997.9 | 2004-04-05 | ||
EP04075997A EP1586318A1 (en) | 2004-04-05 | 2004-04-05 | Thiadiazolidinones as GSK-3 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006139030A true RU2006139030A (ru) | 2008-05-20 |
RU2379300C2 RU2379300C2 (ru) | 2010-01-20 |
Family
ID=34928129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006139030/04A RU2379300C2 (ru) | 2004-04-05 | 2005-04-04 | Ингибиторы gsk-3 |
Country Status (30)
Country | Link |
---|---|
US (2) | US7531561B2 (ru) |
EP (2) | EP1586318A1 (ru) |
JP (1) | JP4995076B2 (ru) |
KR (1) | KR101151647B1 (ru) |
CN (1) | CN1946398B (ru) |
AR (2) | AR048820A1 (ru) |
AT (1) | ATE446090T1 (ru) |
AU (1) | AU2005230392B2 (ru) |
BR (1) | BRPI0508788A (ru) |
CA (1) | CA2559740C (ru) |
CY (1) | CY1109724T1 (ru) |
DE (1) | DE602005017215D1 (ru) |
DK (1) | DK1586319T3 (ru) |
EC (1) | ECSP066858A (ru) |
ES (1) | ES2335505T3 (ru) |
HK (1) | HK1100426A1 (ru) |
HR (1) | HRP20100032T1 (ru) |
IL (1) | IL178125A (ru) |
MA (1) | MA28515B1 (ru) |
MX (1) | MXPA06011194A (ru) |
NO (1) | NO332751B1 (ru) |
NZ (1) | NZ549904A (ru) |
PL (1) | PL1586319T3 (ru) |
PT (1) | PT1586319E (ru) |
RS (1) | RS51340B (ru) |
RU (1) | RU2379300C2 (ru) |
SI (1) | SI1586319T1 (ru) |
TW (1) | TWI352084B (ru) |
WO (1) | WO2005097117A1 (ru) |
ZA (1) | ZA200608221B (ru) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2294931C2 (ru) | 2000-05-11 | 2007-03-10 | Консехо Супериор Инвестигасионес Сьентификас | Гетероциклические ингибиторы гликоген-синтазы киназы gsk-3 |
EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
ES2258406B1 (es) * | 2005-02-10 | 2007-12-01 | Neuropharma, S.A. | Uso de compuestos heterociclicos como agentes neurogenicos. |
EP1749523A1 (en) * | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
US9180118B2 (en) * | 2006-07-18 | 2015-11-10 | University Of Rochester | Thiadiazolidinone derivatives |
WO2008012031A2 (en) * | 2006-07-25 | 2008-01-31 | Universität Bern | Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
ES2445791T3 (es) | 2006-10-21 | 2014-03-05 | Abbvie Deutschland Gmbh & Co Kg | Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3 |
KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
KR100829468B1 (ko) * | 2007-01-17 | 2008-05-16 | 한국화학연구원 | 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2177510A1 (en) | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Allosteric protein kinase modulators |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011151359A1 (en) * | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012041814A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
WO2012065065A1 (en) * | 2010-11-12 | 2012-05-18 | Follica, Inc. | Methods and compositions for modulating hair growth, wound healing and scar revision |
EP2648676A4 (en) | 2010-12-06 | 2016-05-04 | Follica Inc | METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012149335A2 (en) * | 2011-04-28 | 2012-11-01 | Richard Neubig | Small molecule inhibitors of rgs proteins |
EP2527323A1 (en) | 2011-05-24 | 2012-11-28 | Noscira, S.A. | Urea carbonyl disulfide derivatives and their therapeutic uses |
WO2012170657A1 (en) * | 2011-06-07 | 2012-12-13 | Georgetown University | Targeting gsk-3beta for the treatment of parkinson's disease |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
IN2014DN07885A (ru) | 2012-02-24 | 2015-04-24 | Asd Therapeutics Partners Llc | |
RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
CN103992313A (zh) * | 2013-02-18 | 2014-08-20 | 江苏欧威医药有限公司 | 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途 |
CN103992312A (zh) * | 2013-02-18 | 2014-08-20 | 江苏欧威医药有限公司 | 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用 |
WO2015075051A1 (en) | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Allosteric inhibitors of atypical protein kinases c |
CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
JP6663863B2 (ja) | 2014-06-12 | 2020-03-13 | シーダーズ−サイナイ メディカル センター | がん治療のための組成物及び方法 |
CN107151235B (zh) * | 2016-03-04 | 2019-12-13 | 上海市计划生育科学研究所 | 噻二唑烷二酮基gsk3抑制剂在调节***运动能力中的用途 |
JP2019511495A (ja) * | 2016-03-10 | 2019-04-25 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | GSK3β阻害薬チデグルシブによるCDKL5障害の治療 |
US11590110B2 (en) * | 2017-06-06 | 2023-02-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN113827592A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用 |
EP4298088A1 (en) | 2021-02-24 | 2024-01-03 | Teva Pharmaceuticals International GmbH | Solid state forms of tideglusib and process for preparation thereof |
WO2022243973A1 (en) | 2021-05-21 | 2022-11-24 | Amo Pharma Ltd. | Method of treating rna repeat mediated diseases with rna repeat binding compound |
EP4094760A1 (en) | 2021-05-24 | 2022-11-30 | Consejo Superior De Investigaciones Científicas | Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy |
CN115197167B (zh) * | 2022-07-22 | 2023-07-28 | 中国药科大学 | 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
CN117986202A (zh) * | 2024-04-03 | 2024-05-07 | 中国药科大学 | 具有ptpn2抑制活性的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2294931C2 (ru) * | 2000-05-11 | 2007-03-10 | Консехо Супериор Инвестигасионес Сьентификас | Гетероциклические ингибиторы гликоген-синтазы киназы gsk-3 |
ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
-
2004
- 2004-04-05 EP EP04075997A patent/EP1586318A1/en not_active Withdrawn
-
2005
- 2005-04-01 AR ARP050101293A patent/AR048820A1/es not_active Application Discontinuation
- 2005-04-04 WO PCT/EP2005/003613 patent/WO2005097117A1/en active Application Filing
- 2005-04-04 PT PT05075779T patent/PT1586319E/pt unknown
- 2005-04-04 ES ES05075779T patent/ES2335505T3/es active Active
- 2005-04-04 RS RSP-2010/0017A patent/RS51340B/en unknown
- 2005-04-04 ZA ZA200608221A patent/ZA200608221B/xx unknown
- 2005-04-04 SI SI200530879T patent/SI1586319T1/sl unknown
- 2005-04-04 AU AU2005230392A patent/AU2005230392B2/en active Active
- 2005-04-04 JP JP2007506716A patent/JP4995076B2/ja active Active
- 2005-04-04 DK DK05075779.8T patent/DK1586319T3/da active
- 2005-04-04 AT AT05075779T patent/ATE446090T1/de active
- 2005-04-04 RU RU2006139030/04A patent/RU2379300C2/ru active
- 2005-04-04 CA CA2559740A patent/CA2559740C/en active Active
- 2005-04-04 NZ NZ549904A patent/NZ549904A/en active IP Right Revival
- 2005-04-04 MX MXPA06011194A patent/MXPA06011194A/es active IP Right Grant
- 2005-04-04 TW TW094110769A patent/TWI352084B/zh active
- 2005-04-04 EP EP05075779A patent/EP1586319B1/en active Active
- 2005-04-04 BR BRPI0508788-0A patent/BRPI0508788A/pt not_active IP Right Cessation
- 2005-04-04 DE DE602005017215T patent/DE602005017215D1/de active Active
- 2005-04-04 CN CN2005800121414A patent/CN1946398B/zh active Active
- 2005-04-04 PL PL05075779T patent/PL1586319T3/pl unknown
- 2005-04-05 US US11/098,610 patent/US7531561B2/en active Active
-
2006
- 2006-09-14 IL IL178125A patent/IL178125A/en active IP Right Grant
- 2006-09-18 EC EC2006006858A patent/ECSP066858A/es unknown
- 2006-10-02 MA MA29364A patent/MA28515B1/fr unknown
- 2006-10-02 NO NO20064456A patent/NO332751B1/no unknown
- 2006-10-11 KR KR1020067021121A patent/KR101151647B1/ko active IP Right Grant
-
2007
- 2007-07-31 HK HK07108359.1A patent/HK1100426A1/xx unknown
-
2009
- 2009-04-22 US US12/428,442 patent/US8158661B2/en active Active
-
2010
- 2010-01-13 CY CY20101100036T patent/CY1109724T1/el unknown
- 2010-01-18 HR HR20100032T patent/HRP20100032T1/hr unknown
-
2016
- 2016-04-27 AR ARP160101182A patent/AR104417A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006139030A (ru) | Ингибиторы gsk-3 | |
JP2007531782A5 (ru) | ||
RU2008107733A (ru) | Ингибиторы gsk-3 | |
JP2020169171A5 (ru) | ||
RU2020105929A (ru) | Способы и композиции для модулирования сплайсинга | |
RU2008146995A (ru) | N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3 | |
AR055199A1 (es) | Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos | |
JP2009518296A5 (ru) | ||
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
JP2013504593A5 (ru) | ||
AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
RU2006135541A (ru) | Производные аминокислот | |
CA2555804A1 (en) | Polymorphic form of imatinib mesylate and a process for its preparation | |
JP2016510323A5 (ru) | ||
RU2007119585A (ru) | Производные рапамицина и их применение при лечении неврологических заболеваний | |
JP2008511601A5 (ru) | ||
JP2009513571A5 (ru) | ||
RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
HUP0401648A1 (hu) | 6-Hidroxi-izoflavon vegyületek, ezek származékai, valamint ezeket tartalmazó gyógyászati készítmények | |
JP2015508092A5 (ru) | ||
JP2017508816A5 (ru) | ||
CA2617957A1 (fr) | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
AR040133A1 (es) | Derivados de n-acilamino bencil eter | |
JP2011513471A5 (ru) |